A daily pill called daraxonrasib was combined with chemotherapy in an early trial of patients with advanced pancreatic cancer; tumours shrank or disappeared in some patients, and Cancer Research UK called the results “the biggest leap forward in decades” for one of the deadliest cancers.
Data being presented at a European cancer conference show that among 61 participants recently diagnosed with advanced pancreatic cancer that had spread, tumours stopped growing in 90% of patients, shrank or disappeared in just over 60%, and became undetectable on CT scans in about 8%, one in 12 patients.
Pancreatic cancer has the lowest survival rate of all common cancers in the UK. Chemotherapy can shrink tumours temporarily, but the disease often returns, and most patients with advanced disease survive months rather than years.
The trial followed patients for a year and a half on average, and some did not see their cancer return during that time. Longer studies are needed to determine whether any of these cancers can be put into remission and for how long. Doctors stress the treatment should not be seen as a cure.
Daraxonrasib is a KRAS inhibitor that locks on to and shuts off certain mutations, called RAS, found in most pancreatic cancers that drive tumour growth. The drug has already been approved in the US. Similar mutations occur in dozens of other cancers, including lung and ovarian, suggesting the drug might help other patients.
Dr Sam Godfrey of Cancer Research UK told the BBC: "What this new drug has done is it's found a way of drugging the undruggable." He added: "We are finally seeing progress in pancreatic cancer which is so long overdue."
Dr Wungki Park, from Memorial Sloan Kettering Cancer Center in the US and involved in the trial, said the results were extremely encouraging so far. “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”
Prof Elena Garralda, chair of a European cancer conference called EORTC where the work is being presented, said the results were exciting because the combined treatment “could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again.”
There are about 11,500 diagnoses of pancreatic cancer in Britain each year and around 10,200 deaths, according to Cancer Research UK. Actor Alan Rickman died of the disease in 2016, five months after diagnosis.
Analysis
Why This Matters
- Pancreatic cancer has the lowest survival rate of common cancers and few effective treatments; a daily pill that shrinks tumours in a majority of patients could change the outlook for thousands.
- The drug targets a mutation found in most pancreatic cancers and in other cancers, potentially offering a broad new treatment avenue.
- Longer trials are needed, but early results suggest the combination treatment could give patients more time than current chemotherapy alone.
Background
Pancreatic cancer is notoriously difficult to treat because it is often diagnosed at an advanced stage and has few targeted therapies. Most cases are driven by mutations in the RAS family of genes, long considered "undruggable". Daraxonrasib belongs to a new class of KRAS inhibitors that block these mutations, a field that has seen rapid progress in recent years. The drug is already approved in the US for some cancers, but its use in pancreatic cancer is still experimental.
Key Perspectives
Cancer Research UK: Called the results "the biggest leap forward in decades" for pancreatic cancer patients, with Dr Sam Godfrey saying the drug has "found a way of drugging the undruggable" and that progress is "so long overdue."
Dr Wungki Park (Memorial Sloan Kettering Cancer Center): Described the results as extremely encouraging, noting higher response rates and deeper responses that "may eventually translate into longer survival."
Prof Elena Garralda (EORTC): Said the combination treatment "could potentially significantly improve patients' overall survival, as well as the time before tumours start to grow again."
What to Watch
- Results from longer, larger phase 3 trials that will show whether the tumour shrinkage translates into sustained remission or extended survival.
- Whether the drug proves effective against other cancers with similar RAS mutations, such as lung and ovarian.
- Regulatory decisions in the UK and Europe on approval of daraxonrasib for pancreatic cancer.